Welcome to our dedicated page for Dss SEC filings (Ticker: DSS), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Tracking a company that patents anti-counterfeit labels and finances commercial loans can feel like reading five annual reports at once. DSS Inc’s filings weave together packaging security, biotech trials, lending portfolios, and investment gains—details investors can’t afford to miss but rarely have time to untangle.
Stock Titan solves that problem. Our AI reads every DSS Inc quarterly earnings report 10-Q filing, scans each DSS Inc insider trading Form 4 transaction, and highlights what moves markets. Instead of parsing footnotes, you’ll see plain-English callouts—IP valuation swings, biotech milestone expenses, or credit-loss reserves—delivered the moment EDGAR releases them. Looking for the next Form 4 insider transactions real-time alert? Want the DSS Inc annual report 10-K simplified to a five-minute brief? It’s already waiting on this page.
Use the navigation below to answer questions professionals ask every quarter: How did packaging security margins shift? Which executives bought shares after a new patent license? Our coverage spans:
- 8-K material events explained—patent wins, biotech data, or loan impairments
- Proxy statement executive compensation insights for DSS Inc’s diverse leadership
- Earnings report filing analysis comparing segment revenues over time
Whether you’re understanding DSS Inc SEC documents with AI for the first time or need a quick refresh before a call, this hub keeps you current, confident, and ahead of the curve.
DSS, Inc. filed Amendment No. 1 to its Schedule 14A to include the proxy card that was inadvertently omitted; no other changes were made.
The Annual Meeting is set for December 3, 2025, 9:00 a.m. ET at 275 Wiregrass Pkwy, West Henrietta, NY. Stockholders will vote to elect 7 directors, ratify HTL International, LLC as independent auditor for fiscal 2025, and approve an advisory “say‑on‑pay” resolution for executive compensation.
The Board fixed October 6, 2025 as the record date. Shares outstanding were 9,092,518 as of October 6, 2025. Director elections require more “FOR” than “WITHHOLD” votes; auditor ratification and say‑on‑pay pass with a majority of votes cast. The auditor’s anticipated 2025 fees are disclosed as $205,000–$225,000 for reviews and the annual audit. As of the record date, Heng Fai Ambrose Chan beneficially owned 6,017,985 shares (66.2%), with other notable holders including Alset, Inc. and Alset International Limited.
DSS, Inc. Schedule 13D/A shows that Heng Fai Ambrose Chan and affiliated entities control a majority of the company. Mr. Chan reports beneficial ownership of 6,599,380 shares, representing 68.2% of DSS common stock based on 9,092,518 shares outstanding as of September 2, 2025. Affiliated entities include Alset Inc. (4,542,606 shares, 47.0%), Alset International Limited (1,379,943 shares, 15.2%) and Global Biomedical Pte. Ltd. (311,634 shares, 3.4%). On August 20, 2025, Alset Inc. received a $500,000 convertible promissory note convertible at $0.86 per share. On August 28, 2025, Mr. Chan sold 130,679 shares at an average price of $1.3475, in trades between $1.23 and $1.565.
Insider sale disclosed. On 08/28/2025, Heng Fai Ambrose Chan reported selling 130,679 shares of DSS, Inc. common stock at an average price of $1.3475, with trade prices ranging between $1.23 and $1.565. The Form 4 states the sale occurred in multiple trades and the reporting person undertakes to provide full trade-by-trade details upon request.
The filing reports 1,053,796 shares beneficially owned by Mr. Chan following the transaction and identifies additional holdings attributed to him: 1,002,978 shares held by Heng Fai Holdings Limited; 2,581,268 shares held by Alset Inc.; a $500,000 convertible promissory note held by Alset Inc.; 1,068,309 shares held by Alset International Limited; and 311,634 shares held by Global Biomedical Pte. Ltd. The Form 4 is signed 09/02/2025.
DSS, Inc. amended a Form 4 to clarify insider transactions and disclose that on August 20, 2025 the company issued a $500,000 convertible promissory note to Alset Inc. The note allows Alset Inc. to convert principal and accrued interest into common stock at a conversion price of $0.86 per share, or to exchange into any subsequently issued convertible instrument on different terms based on the note balance plus accrued interest. The filing details the beneficial ownership attributable to reporting person Heng Fai Ambrose Chan, including shares held directly and through affiliated entities totaling disclosed positions across Heng Fai Holdings Limited, Alset Inc., Alset International Limited and Global Biomedical Pte. Ltd., and notes the convertible note is exercisable through July 31, 2028.
DSS, Inc. insider transaction summary: On 08/20/2025 the company issued a $500,000 convertible promissory note to Alset Inc. that may be converted into common stock at $0.86 per share. The stated conversion would equate to 581,395 shares.
Reporting person and ownership: The filing is by Heng Fai Ambrose Chan and Alset Inc.; Mr. Chan is identified as a director and a greater-than-10% owner. The filing discloses Mr. Chan's total beneficial ownership of 6,730,059 shares, detailed by holdings across Heng Fai Holdings Limited, direct holdings, Alset Inc., Alset International Limited and Global Biomedical Pte. Ltd.
DSS, Inc. Schedule 13D/A shows that Heng Fai Ambrose Chan and affiliated entities control a large majority of the company’s common stock. Together they beneficially own 6,730,059 shares, representing 69.6% of the 9,092,518 shares outstanding as of August 21, 2025. Alset Inc. alone holds 4,542,606 shares (47.0%). On August 20, 2025, DSS issued a $500,000 convertible promissory note to Alset Inc. that may be converted into common stock at $0.86 per share. The filing lists the ownership breakdown across Heng Fai Holdings Limited, Alset entities and Global Biomedical, and cites a joint filing agreement as an exhibit.
FAQ
What is the current stock price of Dss (DSS)?
What is the market cap of Dss (DSS)?
